|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
MX360823B
(es)
|
2011-05-24 |
2018-11-16 |
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh |
Vacunas individualizadas para el cancer.
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
JP6484558B2
(ja)
|
2012-11-28 |
2019-03-13 |
バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ |
癌ワクチンの組み合せ物
|
|
CA2908434C
(en)
*
|
2013-04-07 |
2021-12-28 |
The Broad Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
NZ721105A
(en)
*
|
2013-12-06 |
2022-04-29 |
Broad Inst Inc |
Formulations for neoplasia vaccines
|
|
EP3082853A2
(en)
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
EP3194970B1
(en)
|
2014-09-10 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Immunogenic mutant peptide screening platform
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016123365A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of Michigan |
Liposomal particles comprising biological molecules and uses thereof
|
|
WO2016128060A1
(en)
*
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
EP3268012A4
(en)
*
|
2015-03-12 |
2018-10-31 |
Health Research, Inc. |
Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
|
|
EP3273944B1
(en)
|
2015-03-25 |
2024-11-20 |
The Regents of The University of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
EP3075389A1
(en)
*
|
2015-03-31 |
2016-10-05 |
Technische Universität München |
T cell receptors and peptides derived by mutations for the treatment of cancer
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
WO2016172722A1
(en)
|
2015-04-23 |
2016-10-27 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CA2982266A1
(en)
*
|
2015-04-27 |
2016-11-03 |
Nicholas MCGRANAHAN |
Method for treating cancer
|
|
WO2016179006A1
(en)
*
|
2015-05-01 |
2016-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
IL293135A
(en)
|
2015-05-13 |
2022-07-01 |
Agenus Inc |
Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
|
|
CR20200476A
(es)
*
|
2015-05-20 |
2020-12-02 |
Dana Farber Cancer Inst Inc |
ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
|
|
TW202241500A
(zh)
*
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
US12150980B2
(en)
|
2015-07-30 |
2024-11-26 |
Modernatx, Inc. |
Concatemeric peptide epitope RNAs
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
JP2018532736A
(ja)
|
2015-10-12 |
2018-11-08 |
ナントミクス，エルエルシー |
チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法
|
|
US11623001B2
(en)
*
|
2015-10-12 |
2023-04-11 |
Nantomics, Llc |
Compositions and methods for viral cancer neoepitopes
|
|
JP2018535202A
(ja)
|
2015-10-12 |
2018-11-29 |
ナントミクス，エルエルシー |
ネオエピトープの反復発見と適応可能な免疫療法およびその方法
|
|
MX387275B
(es)
*
|
2015-10-12 |
2025-03-18 |
Nantomics Llc |
Neoepítopos virales y sus usos
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
CN108601731A
(zh)
*
|
2015-12-16 |
2018-09-28 |
磨石肿瘤生物技术公司 |
新抗原的鉴别、制造及使用
|
|
CA3008437A1
(en)
|
2016-01-08 |
2017-07-13 |
Vaccibody As |
Therapeutic anticancer neoepitope vaccine
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
JP2019509265A
(ja)
*
|
2016-02-11 |
2019-04-04 |
ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ |
二重標的化によるアデノウイルスの皮下送達
|
|
EP3414692A4
(en)
*
|
2016-02-12 |
2020-07-29 |
Nantomics, LLC |
HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
|
|
WO2017222619A2
(en)
|
2016-03-24 |
2017-12-28 |
Nantcell, Inc. |
Sequence arrangements and sequences for neoepitope presentation
|
|
EP3446119A1
(en)
*
|
2016-04-18 |
2019-02-27 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
|
EP3452082A1
(en)
|
2016-05-04 |
2019-03-13 |
Fred Hutchinson Cancer Research Center |
Cell-based neoantigen vaccines and uses thereof
|
|
EP3471778A4
(en)
|
2016-06-20 |
2020-02-19 |
The Regents of The University of Michigan |
COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
|
|
EA201990071A1
(ru)
|
2016-06-20 |
2019-06-28 |
АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. |
Композиция пептидной вакцины
|
|
PL3488443T3
(pl)
*
|
2016-07-20 |
2021-12-20 |
BioNTech SE |
Selekcja neoepitopów jako swoistych dla choroby celów dla terapii o zwiększonej skuteczności
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
EP3535423B1
(en)
*
|
2016-11-07 |
2022-01-05 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Methods for selecting therapy for a cancer patient
|
|
AU2017363308B2
(en)
*
|
2016-11-23 |
2024-08-08 |
Seattle Project Corp. |
Viral delivery of neoantigens
|
|
CN110214275B
(zh)
*
|
2016-12-01 |
2022-12-06 |
南托米克斯有限责任公司 |
肿瘤抗原性加工和呈递
|
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
JP7155470B2
(ja)
*
|
2017-03-31 |
2022-10-19 |
エーシーティー ジェノミックス （アイピー） カンパニー リミテッド |
免疫原性がん特異的エピトープのためのランク付けシステム
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
WO2018195357A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Gritstone Oncology, Inc. |
Neoantigen identification, manufacture, and use
|
|
WO2018200389A1
(en)
*
|
2017-04-24 |
2018-11-01 |
Nantcell, Inc. |
Targeted neoepitope vectors and methods therefor
|
|
CA3062591A1
(en)
|
2017-05-08 |
2018-11-15 |
Gritstone Oncology, Inc. |
Alphavirus neoantigen vectors
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US20200276285A1
(en)
|
2017-06-02 |
2020-09-03 |
Arizona Board Of Regents On Behalf Of Arizona State University |
A method to create personalized cancer vaccines
|
|
CN110720127A
(zh)
*
|
2017-06-09 |
2020-01-21 |
磨石肿瘤生物技术公司 |
新抗原的鉴别、制造及使用
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
KR102684237B1
(ko)
*
|
2017-06-21 |
2024-07-11 |
트랜스진 |
개인 맞춤형 백신
|
|
AU2018287169B2
(en)
*
|
2017-06-22 |
2024-11-14 |
Neogap Therapeutics Ab |
T-cell expansion method and uses
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
JP7763588B2
(ja)
*
|
2017-09-05 |
2025-11-04 |
グリットストーン バイオ インコーポレイテッド |
Ｔ細胞療法用の新生抗原の特定法
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
EP3688165A4
(en)
*
|
2017-09-25 |
2021-09-29 |
Nant Holdings IP, LLC |
VALIDATION OF THE PRESENTATION OF NEOEPITOPES
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
US11779599B2
(en)
|
2017-11-07 |
2023-10-10 |
Coimmune, Inc. |
Methods and uses for dendritic cell therapy
|
|
EP3714275A4
(en)
*
|
2017-11-22 |
2021-10-27 |
Gritstone bio, Inc. |
REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
|
|
WO2019105485A1
(zh)
*
|
2017-12-01 |
2019-06-06 |
上海桀蒙生物技术有限公司 |
个性化癌症疫苗的制备方法
|
|
WO2019122050A1
(en)
|
2017-12-22 |
2019-06-27 |
Isa Pharmaceuticals B.V. |
Methods of immunization
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
JP2021522239A
(ja)
|
2018-04-26 |
2021-08-30 |
アジェナス インコーポレイテッド |
熱ショックタンパク質結合ペプチド組成物およびその使用方法
|
|
MX2020012649A
(es)
*
|
2018-05-25 |
2021-07-02 |
The Wistar Inst |
Neoantígenos especificos de tumor y métodos de uso de estos.
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
EP3813848A4
(en)
*
|
2018-06-27 |
2022-07-20 |
ModernaTX, Inc. |
Personalized cancer vaccine epitope selection
|
|
WO2020020444A1
(en)
*
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
EP3826669A2
(en)
|
2018-07-26 |
2021-06-02 |
Frame Pharmaceuticals B.V. |
Off-the-shelf cancer vaccines
|
|
CA3109430A1
(en)
*
|
2018-09-05 |
2020-03-12 |
Vaximm Ag |
Neoantigen targeting dna vaccine for combination therapy
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
CN112771214B
(zh)
|
2018-09-27 |
2025-06-13 |
耐考德治疗股份有限公司 |
用于选择新表位的方法
|
|
CN109337873A
(zh)
*
|
2018-09-30 |
2019-02-15 |
北京鼎成肽源生物技术有限公司 |
一种lrff细胞
|
|
JP2022506839A
(ja)
*
|
2018-11-07 |
2022-01-17 |
モデルナティエックス インコーポレイテッド |
Ｒｎａがんワクチン
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
GB201821207D0
(en)
|
2018-12-24 |
2019-02-06 |
Tcer Ab |
Immunotherapy therapy
|
|
AU2020232971A1
(en)
*
|
2019-03-01 |
2021-09-23 |
Scott R. BURKHOLZ |
Design, manufacture, and use of personalized cancer vaccines
|
|
EP3935638B1
(en)
*
|
2019-03-08 |
2025-11-05 |
Nantomics, LLC |
System and method for variant calling
|
|
CN110059625B
(zh)
*
|
2019-04-18 |
2023-04-07 |
重庆大学 |
一种基于mixup的人脸训练与识别方法
|
|
JP2022533861A
(ja)
*
|
2019-05-03 |
2022-07-26 |
ギレム リチャード |
がんにおける新抗原
|
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
EP3983008A4
(en)
*
|
2019-06-11 |
2023-07-12 |
Iogenetics, LLC. |
IMMUNOTHERAPIES BASED ON NEO-ANTIGENS
|
|
EP3987028A4
(en)
*
|
2019-06-21 |
2023-07-19 |
Kernal Biologics, Inc. |
MODIFIED ONCOSELECTIVE PROTEIN EXPRESSION
|
|
CN110514845B
(zh)
*
|
2019-08-22 |
2022-09-27 |
深圳新合睿恩生物医疗科技有限公司 |
一种肿瘤新生抗原免疫原性检测方法及检测平台
|
|
CN116688107A
(zh)
*
|
2019-09-06 |
2023-09-05 |
北京微九九科技有限公司 |
一种肿瘤疫苗的制备方法及使用该方法制备的肿瘤疫苗
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
WO2021092436A1
(en)
*
|
2019-11-08 |
2021-05-14 |
The Regents Of The University Of California |
Identification of splicing-derived antigens for treating cancer
|
|
JP7496111B2
(ja)
*
|
2019-12-24 |
2024-06-06 |
国立大学法人東京工業大学 |
サブキャリア変調方式テラヘルツレーダー
|
|
US11011253B1
(en)
*
|
2020-07-09 |
2021-05-18 |
Brian Hie |
Escape profiling for therapeutic and vaccine development
|
|
CA3187258A1
(en)
|
2020-08-06 |
2022-02-10 |
Karin Jooss |
Multiepitope vaccine cassettes
|
|
US11421015B2
(en)
|
2020-12-07 |
2022-08-23 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
CN116710115A
(zh)
|
2020-11-20 |
2023-09-05 |
思维疗法股份有限公司 |
用于优化的肽疫苗的组合物和方法
|
|
US11058751B1
(en)
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
EP4255474A4
(en)
*
|
2020-12-07 |
2025-06-18 |
Iogenetics, LLC. |
PERSONALIZED IMMUNOTHERAPIES
|
|
US20240024439A1
(en)
*
|
2020-12-07 |
2024-01-25 |
Iogenetics, Llc |
Administration of anti-tumor vaccines
|
|
GB202104715D0
(en)
|
2021-04-01 |
2021-05-19 |
Achilles Therapeutics Uk Ltd |
Identification of clonal neoantigens and uses thereof
|
|
US11464842B1
(en)
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
CN113069537A
(zh)
*
|
2021-04-29 |
2021-07-06 |
江苏欣生元生物科技有限公司 |
一种基于ras变异新生抗原表位的融合蛋白纳米疫苗及其制备方法
|
|
CN117321189A
(zh)
|
2021-04-30 |
2023-12-29 |
泰根制药有限公司 |
淋巴细胞的单血管扩增
|
|
CN112972666B
(zh)
*
|
2021-05-12 |
2021-08-31 |
山东兴瑞生物科技有限公司 |
个性化基因修饰肿瘤dc疫苗的制备方法
|
|
US20220383996A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Amazon Technologies, Inc. |
Assigning peptides to peptide groups for vaccine development
|
|
WO2023043888A1
(en)
*
|
2021-09-15 |
2023-03-23 |
Celloram Inc. |
Method of treating cancer
|
|
TW202340474A
(zh)
|
2022-01-11 |
2023-10-16 |
大陸商深圳市珈鈺生物科技有限公司 |
樹突細胞腫瘤疫苗和其用途
|
|
CA3253072A1
(en)
*
|
2022-05-11 |
2023-11-16 |
Fundacao D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Centro De Investig Da |
METHOD FOR PREPARING AND MULTIPLYING AN IMMUNE CELL POPULATION FOR CANCER THERAPY, BIOLOGICAL ACTIVITY TEST FOR TUMOR RECOGNITION, PREPARATION OF BIOLOGICAL VACCINES AND EPITOPE TARGET FOR ANTIBODIES
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024097864A1
(en)
|
2022-11-02 |
2024-05-10 |
Tigen Pharma Sa |
Expansion of lymphocytes
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
CN120600110B
(zh)
*
|
2025-08-06 |
2025-12-09 |
上海交通大学医学院附属仁济医院 |
基于人工智能的多变病原t细胞表位精准筛选方法
|